JonesTrading analyst Prakhar Agrawal reiterated a Buy rating on Arcutis Biotherapeutics (NASDAQ:ARQT) on Tuesday, setting a price target of $51, which is approximately 45.38% above the present share price of $35.08.
Agrawal expects Arcutis Biotherapeutics to post earnings per share (EPS) of -$1.01 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Arcutis Biotherapeutics, with an average price target of $51.33.
The analysts price targets range from a high of $55 to a low of $48.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$38.3 million. The company's market cap is $1.72 billion.
According to TipRanks.com, JonesTrading analyst Prakhar Agrawal is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 12.0% and a 83.33% success rate.
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.